key: cord-0758566-w59nfvzf
authors: Muhsen, Khitam; Maimon, Nimrod; Mizrahi, Ami; Bodenneimer, Omri; Cohen, Dani; Maimon, Michal; Grotto, Itamar; Dagan, Ron
title: Effectiveness of BNT162b2 mRNA COVID-19 vaccine against acquisitions of SARS-CoV-2 among health care workers in long-term care facilities: a prospective cohort study
date: 2021-10-26
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab918
sha: a4f66218dcc09a8eaac2ff6bd07ba82cb3b65906
doc_id: 758566
cord_uid: w59nfvzf

OBJECTIVE: We assessed vaccine effectiveness (VE) of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 acquisition among health care workers (HCWs) of long-term care facilities (LTCFs). METHODS: This prospective study, in the framework of "Senior Shield" program in Israel, included routine, weekly nasopharyngeal SARS-CoV-2 RT-PCR testing from all LTCF HCWs since July 2020. All residents and 75% of HCWs were immunized between December 2020 and January 2021. The analysis was limited to HCWs adhering to routine testing. Fully vaccinated (14+ days after second dose; n=6960) and unvaccinated HCWs (n=2202) were simultaneously followed until SARS-CoV-2 acquisition, or end of follow-up, April 11, 2021. Hazard ratios (HRs) for vaccination vs. no vaccination were calculated (Cox proportional hazards regression models, adjusting for socio-demographics and residential-area COVID-19 incidence). VE was calculated as [(1– HR)×100]. RT-PCR cycle threshold values (Cts) were compared between vaccinated and unvaccinated HCWs. RESULTS: At >14 days post second dose, 40 vaccinated HCWs acquired SARS-CoV-2 (median follow-up, 66 days; cumulative incidence 0.6%) vs. 84 unvaccinated HCWs (median follow-up 43 days; cumulative incidence, 5.1%); HR=0.11 (95% CI 0.07, 0.17), unadjusted VE=89% (95% CI 83%, 93%). Adjusted VE beyond seven days and >14 days post second dose were similar. The median PCR Cts targeting ORF1ab gene among 20 vaccinated and 40 unvaccinated HCWs was 32.0 vs. 26.7, respectively, p=0.008. CONCLUSIONS: VE following two doses of BNT162b2 against SARS-CoV-2 acquisition in LTCF HCWs was high. The lower viral loads among SARS-CoV-2 positive HCWs suggests further reduction in transmission.

The BNT162b2 mRNA COVID-19 vaccine was the first vaccine to receive emergency use authorization, with a 95% efficacy against COVID-19 in phase III clinical trial [1, 2] .

In December 19, 2020, Israel launched a national vaccination campaign using BNT162b2 vaccine, initially prioritizing health care workers (HCWs) and individuals aged 60 years and older. Gradually COVID-19 immunization was expanded to all individuals aged 16 years or older. By April 11, 2021, nearly 53% of 16 years or older individuals were immunized with two doses. The respective figure was 85% for those aged 60 years or older [3] .

Real-life observational studies from Israel have demonstrated effectiveness of ≥95% against COVID-19 after immunization with two doses [4, 5] , consistent with studies in other countries [6, 7] . However, vaccine effectiveness against disease does not predict necessarily the full potential impact of a vaccine, since it does not measure its ability to reduce transmission, an important factor in public health policy. Asymptomatically infected individuals are important in the transmission of SARS-CoV-2, contributing to the evolution of the pandemic [8] . Estimating SARS-CoV-2 acquisition (encompassing both symptomatic and asymptomatic infections) is problematic, mainly due to differences in demographics and other personal characteristics, incentives to be tested, and risk-associated behavior between vaccinated and unvaccinated individuals, resulting in potential confounding and selection bias [9] . Thus, the effectiveness of BNT162b2 vaccine on SARS-CoV-2 transmission and the resulting indirect (herd) protection has not yet been fully elucidated.

HCWs are at risk for SARS-CoV-2 infection [10], and they might transmit the virus to their patients, often a high-risk population of severe COVID-19. Therefore, determining the risk of SARS-CoV-2 acquisition is of utmost importance among HCWs. It was shown that BNT162b2 administered to HCWs was inversely associated with SARS-CoV-2 infection risk A c c e p t e d M a n u s c r i p t 5 [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The vaccine effectiveness (VE) of two doses was assessed in four studies, ranging from 85% to 97%, and mostly did not determine VE against asymptomatic infections separately [11, 16, 17, 19, 20] , except of one showing lower VE against asymptomatic SARS-CoV-2 infection than symptomatic infection [21] .

Since the residents of long-term care facilities (LTCF) are a vulnerable population, a national LTCF protection program, "Senior Shield", was initiated on April 2020 in Israel [22] . In this program, routine, government-funded, weekly screening of SARS-CoV-2 infection by RT-PCR testing of nasopharyngeal swabs from all LTCF HCWs has been implemented since July 2020. Starting on December 22, 2020, BNT162b2 vaccine was offered to all LTCFs HCWs and residents. This task was completed by the end of January-2021, after having enrolled all institutions in Israel. Among HCWs, approximately 75% were vaccinated and 16% were known convalescent. Weekly nasopharyngeal testing of SARS-CoV-2 detection has been ongoing without interruption. We took advantage of the active weekly surveillance of PCR testing, with the primary objective to assess the effectiveness of the BNT162b2 vaccine in preventing the acquisition of SARS-CoV-2 in fully vaccinated HCWs.

Since SARS-CoV-2-neutralizing antibody titers were shown to be highest after seven and 14 days following immunization with the second BNT162b2 dose [23] and following evidence from previous studies [2, 4, 5] , we hypothesized that the risk ofSARS-CoV-2 infection seven or 14 days following immunization will be lower among vaccinated compared to unvaccinated HCWs.

A prospective cohort study was conducted among HCWs aged 16-65 years who took part in "Senior Shield" program [22, 24] . Since July 2020, all HCWs of all LTCFs in Israel have been required to undergo weekly screening for the detection of asymptomatic SARS-CoV-2 A c c e p t e d M a n u s c r i p t 6 infection via nasopharyngeal RT-PCR testing. Those found positive were provided with the recommended care and requested to be quarantined for 10-14-days. All HCWs and tenants at the LTCFs with confirmed cases were repeatedly screened by RT-PCR until all three consecutive negative results. The program was active in 1078 LCTFs, both public and private institutions, with 46,024 HCWs (Supplementary material 1).

1) Adherence to routine screening for SARS-CoV-2 infection by RT-PCR testing.

Specifically, HCWs who had ≥12 out of the 20 of the planned screening tests for the period September 2020 through January 2021; the rationale by utilizing this criterion was that we considered adherence to testing as a health behaviour, a main confounder in vaccine effectiveness studies, and to better identify current/active HCWs.

2) Working in LCTFs that vaccinated ≥75% of their employees collectively during three consecutive days.

3) Being RT-PCR negative for SARS-CoV-2 infection by the date of immunization with the second vaccine dose.

Unvaccinated HCWs at baseline, who were vaccinated later, were censored upon receiving their first vaccination dose in the primary analysis. Excluded from the primary analysis were HCWs working at institutions that did not have a collective immunization period, partially vaccinated HCWs at baseline (i.e. received one vaccine dose), and those who had a RT-PCRconfirmed SARS-CoV-2 infection before immunization, or between immunization with the second dose until day seven or 14 days post immunization.

A secondary approach was implemented in which data of all vaccinated HCWs were analyzed regardless of whether they worked at an institution with collective immunization period, to increase the generalizability of the study findings and reduce potential selection A c c e p t e d M a n u s c r i p t 7 bias. In this analysis, HCWs (n=1130) who were initially unvaccinated but received the vaccine later, contributed follow-up time to both the vaccinated and unvaccinated groups.

Data were obtained through Senior Shield program on demographics, results of the RT-PCR tests, and COVID-19 immunization.

The follow-up starting dates were more than seven and >14 days post vaccination with the second BNT162b2 dose. Since for each LTCF, vaccination was done within three consecutive days, the second of the three consecutive days was defined at the "index" day for unvaccinated HCWs and events were counted after seven and >14 days after this date. By this, we created a matched (common) calendrer baseline for the vaccinated and unvaccinated groups at the institution level (mostly calendar weeks 4-5 in 2021), which was important due to substantial changes in COVID-19 incidence during the study period. Both groups were followed until the earliest of the following events: acquisition of SARS-CoV-2 infection, or end of follow-up on April 11, 2021. For the unvaccinated individuals who opted to be vaccinated after the index date, the follow-up ended on the date of the first dose administration. We also tested an alternative approach, in which vaccinated and unvaccinated HCWs were not matched by baseline calendar time and were followed until the earliest of the mentioned above events. The start follow-up date for unvaccinated group in this analysis was determined as the average date of vaccination with the second vaccine dose January 30 2021. RT-PCR screening, eliminating potential effect of immunization on testing. HCWs who tested positive between the first and the second dose administration and up to day 14 after the second dose administration were excluded from the primary analysis. RT-PCR screening policy for SARS-CoV-2 detection in the framework of the Senior Shield program was unchanged throughout the study. A secondary endpoint was SARS-CoV-2 acquisition more than seven days after the second dose administration.

The independent variable: COVID-19 vaccination status (a dichotomous variable). Fully vaccinated HCWs were defined as more than 14 days post two doses of BNT162b2 vaccine given three weeks apart (± 4 days). HCWs who did not receive any dose were classified as unvaccinated.

The following variables were considered as confounders: age (years), gender, population group (general Jewish population, ultraorthodox Jewish population or Arab population), residential socioeconomic status (SES) [25] and residential area incidence rates of COVID-19. The residential area incidence rates (per 10,000) was categorized by as low (<15), intermediate (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) and high (25-457). We also assessed the level of vaccination uptake among all employees per each institution. 

Baseline characteristics of the study groups were described using means and standard deviations (SD) for continuous variables and counts, and percentages for categorical variables.

Curves of cumulative incidence of SARS-CoV-2 infection among vaccinated and unvaccinated groups were created using Kaplan-Meier survival analysis and compared with the log-rank test. Cox proportional hazards regression models [28] with follow-up time (days) as the time scale were constructed to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for SARS-CoV-2 acquisition. The "facilities" were included in the analysis as strata; i.e. the variable "facility" was treated as a "matching" variable. . Independent variables were COVID-19 vaccination, gender, age, residential SES and the cumulative incidence of SARS-CoV-2 infection by residential area. We repeated the analysis while including the variable "level of vaccine uptake" in the model, to assess potential indirect (herd) protection.

The variables "population group" and "residential SES" were significantly correlated (lower residential SES among Arabs than Jews, Spearman's rank correlation coefficient -0.59, p<0.0001), therefore only residential SES was included in the multivariable model.

We calculated HR for vaccination compared with no vaccination. VE was calculated as: (1-HR)×100 and it was calculated from both >14 and more than seven days after the second vaccine dose until the end of the follow-up. The proportional hazards assumption was tested using the Schoenfeld residuals, with no violations found.

Sensitivity analysis was undertaken, in which the analyses were repeated following our secondary approach that included all vaccinated HCWs, regardless of whether their institution had collective vaccination period. We did not have the exact reasons for non-A c c e p t e d M a n u s c r i p t 10 adherence or low adherence of HCWs to RT-PCR testing, but mostly it was attributed to logistic reasons. Thus, we reanalyzed the data while considering various levels of adherence to testing to explore possible impact of potential selection bias.

Differences in the median Ct values Ct values from RT-PCR test between fully vaccinated and unvaccinated HCWs were assessed using Mann-Whitney U test.

Two-sided p value <0.05 was considered statistically significant. Analyses were done using R software, version 4.0.4.

The study protocol was approved by the institutional review board of the Soroka University Medical Center, Beer-Sheva, Israel.

Among 46,024 HCWs, 15,535 were adherent to routine screening for SARS-CoV-2 infection by RT-PCR testing; of these, 9162 (n=6960 vaccinated and n=2202 unvaccinated) worked in LTCFs in which employees were vaccinated within three consecutive days, and included in the main (calendar-matched) analysis (Figure 1) . The mean age of the study sample was 46.2 years and most (79.5%) participants were females. The vaccinated group was older, included more males and individuals who lived in towns/communities of high SES rank and low COVID-19 incidence rates than the unvaccinated group. Vaccinated and unvaccinated HWCs were distributed across all levels of vaccine uptake, although slightly more unvaccinated HCWs worked in institutions with lower uptake (Table 1) . Accordingly, we adjusted for these variables in multivariable models.

Among the vaccinated group, 40 HCWs acquired SARS-CoV-2 infection >14 days post second dose (median follow-up, 66 days; cumulative incidence 0.6%). Among the unvaccinated group, 84 HCWs acquired SARS-CoV-2 (median follow-up 43 days;

A c c e p t e d M a n u s c r i p t 11 cumulative incidence, 5.1%) (Figure 2) . Significantly lower risk of acquisition of SARS-CoV-2 was found among vaccinated than unvaccinated HCWs (HR 0.11 [95% CI 0.07, 0.17]), yielding unadjusted VE of 89% (95% CI 83%, 93%). Multivariable Cox proportional hazards regression model that controlled for potential confounders showed an adjusted VE of 89% (95% CI 83%, 93%) >14 days after immunization with the second dose ( Table 2 ). The level of vaccine uptake by the employees in each institution was inversely related SARS-CoV-2 infection incidence, but it did not affect the VE estimates (Supplementary Table 1) .

The results were similar when considering the period of more than seven days after the second dose (Supplementary Table 2 

Sensitivity analysis that included all vaccinated HCWs (n=11,496) who received two vaccine doses and unvaccinated HCWs (n=3151) (Supplementary Figure 2) , showed comparable characteristics between these groups and those who were included in the primary analysis (Supplementary Table 4 ). During a median follow-up of 65 and 41 days of vaccinated and unvaccinated HCWs, respectively, the cumulative incidence of SARS-CoV-2 infection more than 14 days post second dose was 1.2% (n=131 events) and 7.9% (n=182 events), respectively (Supplementary Figure 3) 

Information on Ct values from RT-PCR test was available for 64 HCWs (20 were vaccinated and 44 were unvaccinated) (Figure 3) . The median Ct value was significantly higher among fully vaccinated individuals than unvaccinated ones 32.0 (IQR=14.5) vs. 26.7 (IQR=8.8), p=0.008.

In this study among HCWs in LTCFs, BNT162b2 VE against SARS-CoV-2 acquisition was 89% after 14 days post vaccination with the second dose. This finding was consistent after adjustment for confounders, and when considering the period of more than seven days after second dose. Our results were obtained in a "well-controlled" setting, by assessing comparable groups in terms of utilization of SARS-CoV-2 RT-PCR screening tests and follow-up calendar, during a mass deployment of COVID-19 immunization and substantial changes in the disease incidence in Israel [4, 5, 29] . Our estimate of 89% effectiveness of two-dose BNT162b2 regimen against SARS-CoV-2 acquisition is consistent with findings of a study from England that reported 85% vaccine A c c e p t e d M a n u s c r i p t 13 effectiveness against any SARS-CoV-2 infection among HCWs [11] . Other studies reported higher effectiveness of >95% [16, 17] , a discrepancy that might be due methodological variation.

We found significantly higher Ct values among vaccinated than unvaccinated HCWs. It was Our study has limitations. We did not have data on symptoms, since the main goal of the RT-PCR screening was to detect and quarantine positive workers in order to prevent/stop the virus transmission. Thus, we were not able to produce separate VE estimates for asymptomatic or symptomatic infections as was the case in other studies among HCWs. We included working adults aged 65 years or less, thus severe comorbidities likely are not an issue in this population. Moreover most participants were women, thus direct extrapolation to the general population might be limited. We assessed only short-term protection following vaccination, therefore could not to assess potential waning immunity. Our study was undertaken during a period in which the Alpha variant (B.1.1.7) SARS-CoV-2 variant was predominant [4] . Current evidence showed waning immunity about six months following vaccination [38, 39] with the second BNT162b2 dose, and reduced 40-50% effectiveness against the Delta variant, although effectiveness against COVID-19 hospitalizations was 89%

[40]. Most (75%) HCWs in our cohort received BNT162b2 vaccine and 25% were unvaccinated HCWs. Likely these groups differ in health behaviors. To account for these factors, we included in the primary analysis adherent HCWs to routine screening for SARS-CoV-2 infection, prior to and during COVID-19 vaccine deployment, thus creating homogeneous groups in term of RT-PCR testing uptake and minimizing potential effect of immunization on testing.

A c c e p t e d M a n u s c r i p t 14 Information on Ct values was available for ~50% of infected HCWs, this is due differences between the laboratories in reporting format of the RT-PCR test results. The missingness was not related to vaccination status of the HCWs, since the laboratories did not have background information on the HCWs.

Our study has several strengths. We prospectively and systematically collected samples periodically from all our participants, reducing the potential biases in comparing vaccinated to unvaccinated HCWs. Our analytical approach adjusted for potential confounders that might affect both vaccine uptake and COVID-19 incidence, and importantly matching on calendar time, during a period with marked fluctuations in disease incidence. Lastly, we considered multiple sensitivity analyses showing consistent findings comparable with the main analysis. A c c e p t e d M a n u s c r i p t 23 A c c e p t e d M a n u s c r i p t 28 Figure 3 

Emergency use authorization for Pfizer-BioNTech COVID-19 vaccine

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

COVID-19 Dashboard

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases

Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers

Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia

Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region

Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel

BNT162b2 vaccine uptake and effectiveness in UK healthcare workers -a single centre cohort study